Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 ...

Partner Therapeutics announces positive data from post hoc analysis of eNRGy trial evaluating treatment beyond progression with zenocutuzumab in patients with advanced NRG1+ NSCLC ...

Although not as essential as in other tumor types, genomic testing is increasingly playing a role in guiding treatment for ...

Broeden Morss was diagnosed with high-risk acute myeloid leukemia this past December after his mother, Kerynn, noticed he ...

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

At Daylight Studio Flatiron, “Ancestral Futures” FW26/27 takes center stage in the luminous space shaping NYFW most ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

17-year-old Broeden Morss was diagnosed with high-risk acute myeloid leukemia this past December after his mother, Kerynn, noticed he wasn’t able to do his usual activities and was extremely tired.

The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday.

Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in ...

New genomic research suggests our species descended from a deep fusion between two ancient lineages — one of them a mysterious “ghost.” ...

Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported ...